SCHEMBL5105975

SCHEMBL5105975

CNc1ncnc2c1ncn2-c1ccc(N)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ YTHDC1 Q96MU7 2/20 0.54
▸ PI4KA P42356 7/20 0.51
▸ PI4K2B Q8TCG2 7/20 0.51
▸ PI4K2A Q9BTU6 7/20 0.51
▸ PI4KB Q9UBF8 7/20 0.51
▸ EGFR P00533 1/20 0.50
▸ PDE4A P27815 2/20 0.43
▸ PDE4B Q07343 2/20 0.43
▸ PDE4C Q08493 2/20 0.43
▸ PDE4D Q08499 2/20 0.43
▸ PDE5A O76074 1/20 0.43
▸ PDE1A P54750 1/20 0.43
▸ PDE1B Q01064 1/20 0.43
▸ PDE3B Q13370 1/20 0.43
▸ PDE1C Q14123 1/20 0.43
▸ PDE3A Q14432 1/20 0.43
▸ ADORA2A P29274 1/20 0.41
▸ ADORA3 P0DMS8 1/20 0.41
▸ ADORA1 P30542 1/20 0.41
▸ MKNK1 Q9BUB5 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28496042 0.85 PI4KA (0.51) PI4KAPI4K2BPI4K2API4KBEGFR
SCHEMBL5112127 0.81 YTHDC1 (0.49) YTHDC1PI4KAPI4K2BPI4K2API4KB
SCHEMBL3538512 0.80 PI4KA (0.77) PI4KAPI4K2BPI4K2API4KBEGFR
SCHEMBL19350813 0.77 PI4KA (0.62) PI4KAPI4K2BPI4K2API4KBEGFR
SCHEMBL5118492 0.77 PI4KA (0.51) PI4KAPI4K2BPI4K2API4KBEGFR
SCHEMBL5108460 0.75 PTK2 (0.48) PI4KAPI4K2BPI4K2API4KBEGFR
SCHEMBL5105972 0.75 PI4KA (0.52) PI4KAPI4K2BPI4K2API4KBEGFR
SCHEMBL23771392 0.73 YTHDC1 (0.66) YTHDC1PDE4APDE4BPDE4CPDE4D
SCHEMBL20551317 0.72 CCNE2 (0.45) PI4KAPI4K2BPI4K2API4KBEGFR
SCHEMBL16179009 0.72 PDE4A (0.49) YTHDC1PI4KAPI4K2BPI4K2API4KB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8609656-B2 Heteroarylphenylurea derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2013-12-17 — — US disclosed
US-20080119466-A1 Heteroarylphenylurea Derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2008-05-22 — — US disclosed
US-20080119466-A1 Heteroarylphenylurea Derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2008-05-22 — — US disclosed
EP-1724258-A1 HETEROARYLPHENYLUREA DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2006-11-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119466-A1 Heteroarylphenylurea Derivative CHRM1, CBR3, CHRM2 YTHDC1 1556/4885PI4KA 4459/4885PI4K2B 3789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback